Compass Therapeutics, Inc. (CMPX) Investor Relations Documents

Compass Therapeutics, Inc. (CMPX) investor relations documents from the company's IR site: 1 presentation, 12 press releases; latest deck 2026-08-14. Read in-app with summaries. First-party data.

Corporate Presentation: Compass Therapeutics presents its oncology pipeline, highlighting Tovecimig's potential BLA filing in late 2026 for 2L/3L BTC, with $180M cash.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-14PresentationCorporate Presentation
2026-08-06Press releaseCompass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
2026-07-17Press releaseCompass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
2026-05-28Press releaseCompass Therapeutics to Participate in Upcoming June Investor Events
2026-05-21Press releaseCompass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Trea
2026-05-12Press releaseCompass Therapeutics to Participate in Upcoming May Investor Events
2026-05-05Press releaseCompass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
2026-04-27Press releaseTovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Bi
2026-04-24Press releaseCompass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Pati
2026-03-05Press releaseCompass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
2026-01-06Press releaseCompass Therapeutics Provides Corporate Update
2020-02-28Press releasePDF Version
Press releaseCompass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Trac

CMPX overview · CMPX earnings · CMPX financials · CMPX KPIs · CMPX ownership · CMPX peers · CMPX filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.